Joanna Smith
Psychiatric/Mental Health · Edmond, OKNPI 1942718358
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,555 and has fallen 68.3% since, to $493 in 2025.
Across 126 payments — averaging $29.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$670
- Otsuka America Pharmaceutical, Inc.$612
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$425
- Johnson & Johnson$352
- Neurocrine Biosciences, Inc.$336
- Acadia Pharmaceuticals Inc$299
- plus $1K from 10 others
What the payments were for
- Food & beverage$3,763100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,763 in reported general payments places this provider in the 75th percentile of 231 psychiatric/mental health providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 18 | $52,931 |
| Abilify MaintenaAripiprazole | 13 | $38,639 |
| TrintellixVortioxetine Hydrobromide | 38 | $13,045 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 21 | $9,452 |
| Divalproex Sodium | 103 | $5,141 |
| Clozapine | 50 | $4,251 |
| Olanzapine | 77 | $3,936 |
| Buspirone Hcl | 125 | $2,789 |
| Scopolamine | 12 | $2,601 |
| Quetiapine Fumarate | 134 | $2,504 |
| Fluvoxamine Maleate | 37 | $2,347 |
| Naltrexone Hcl | 35 | $2,321 |
| Lorazepam | 127 | $2,261 |
| Risperidone | 79 | $1,952 |
| Donepezil Hcl | 14 | $1,720 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $352 | $52,93118 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $612 | $38,63913 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $74 | $13,04538 claims |
| Almatica Pharma LLCSertraline Hcl | $11 | $59835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 231 psychiatric/mental health providers in Oklahoma.
Other psychiatric/mental health in Edmond
- Meryl AaronEdmond$23K
- Amber BrownEdmond$15K
- Rebecca DanielEdmond$6K
- Cristen DegraffenreidEdmond$4K
- Fernanda CooleyTulsa$16K
- Amy BoggsNorman$15K
- Sylvie MawohOklahoma City$14K
- Nicole HolzerNorman$12K
- Pramila TraxlerTulsa$12K
- Sasha LounmalaMuskogee$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.